Move strengthens Kendle's position as a global clinical development partner to the biopharmaceutical industry
CINCINNATI, June 1 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the opening of offices in Kuala Lumpur, Malaysia; Bangkok, Thailand; and Manila, Philippines. The new operations provide Kendle's global biopharmaceutical customers with access to additional patient populations while strengthening the Company's position as a global clinical development partner. Kendle has been active in the Asia/Pacific region since 1998 and currently operates offices in Beijing, Hong Kong and Shanghai, China; New Delhi and Ahmedabad, India; Singapore; and Sydney and Melbourne, Australia.
"Kendle is one of the few truly global providers offering comprehensive Phase I-IV solutions to meet the needs of the world's biopharmaceutical industry," said Candace Kendle, PharmD, Chairman and CEO. "Our expanded presence in the Asia/Pacific region enhances opportunities for patient access, creates efficiencies in the clinical development process and overall strengthens Kendle's ability to foster global strategic alliances with the leading companies in the biopharmaceutical industry."
Kendle's expansion in Asia/Pacific reflects the growing importance of the region to the global clinical research market. Recent research by the Tufts Center for the Study of Drug Development indicates that within the next three years, as much as 65 percent of all FDA-regulated clinical trials will be conducted outside the United States, with a significant number of these studies moving to Asia. Clinical research organizations with a sound understanding of the Asian marketplace will have a sizeable advantage.
"With more than half of the world's population, Asia offers an abundance of patients in nearly every therapeutic area," added Dr. Ross Horsburgh, Vice President, Global Clinical Development - Asia/Pacific. "Furthermore, governments have highlighted biopharmaceutical development as a key pillar to their economies, resulting in much more favorable environments for global clinical development work."
The new Kendle offices are located at:
Kendle Sdn Bhd Level 16, 1 Sentral Jalan Stesen Sentral 5 KL Sentral, 50470 Kuala Lumpur Malaysia Kendle C.R.O. (Thailand) Co., Ltd. 23/F M Thai Tower, All Seasons Place 87 Wireless Road Lumpini, Phatumwan Bangkok 10330 Thailand Kendle CRO Philippines, Inc. 18th Floor Philamlife Tower 8767 Paseo de Roxas Makati City 1226, Philippines
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. Such forward-looking statements include, but are not limited to Kendle's existing and planned growth and market penetration in the Asia Pacific region, including India. Kendle cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained herein. Such factors include (a) fluctuation in the exchange rate of the U.S. dollar to other currencies; (b) the ability to set up and sustain growth entities in the above described regions; (c) changes in the markets for the company's service offerings; (d) changes in the market for customers' products; and (e) other risks as detailed from time to time in Kendle's SEC reports, including its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Annual Reports on Form 10-K.
|SOURCE Kendle International Inc.|
Copyright©2009 PR Newswire.
All rights reserved